NCT00562653

Brief Summary

The purpose is to evaluate autoantibodies in infective endocarditis patients before, at the beginning of treatment, and after the end of the treatment, and to correlate the autoantibodies in the presence of clinical symptoms.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2007

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

November 20, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 22, 2007

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2008

Completed
Last Updated

November 22, 2007

Status Verified

November 1, 2007

First QC Date

November 20, 2007

Last Update Submit

November 21, 2007

Conditions

Infective Endocarditis

Keywords

profile autoantibodiesclinical symptoms

Study Arms (3)

1

infective endocarditis patients before treatment

2

infective endocarditis treatment after treatment

3

control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

infective endocarditis patients

You may qualify if:

  • Infective endocarditis patients by DUKES criteria

You may not qualify if:

  • HIV positive
  • Patients suffering from other infective diseases other than endocarditis.
  • Patient suffering from collagen diseases for example: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), mixed connective tissue disease, and scleroderma.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sourasky Medical Center

Tel Aviv, Israel

Location

Biospecimen

Retention: NONE RETAINED

serum

MeSH Terms

Conditions

Endocarditis

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Victoria Bogusllavsky, MD

    Sourasky Medical Center, Internal Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

November 20, 2007

First Posted

November 22, 2007

Study Start

November 1, 2007

Study Completion

November 1, 2008

Last Updated

November 22, 2007

Record last verified: 2007-11

Locations

IL(1)